cup
RECEIVED BY DTIE OCT 21 1971

UCLA - 12 - 8 38

MASTER

UNIVERSITY OF CALIFORNIA, LOS ANGELES

LABORATORY OF NUCLEAR MEDICINE AND RADIATION BIOLOGY

CONTRACT NO. AT (04-1) GEN-12

DISTRIBUTION OF THIS DOCUMENT IS UNLIMITED

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency Thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

DISCLAIMER

Portions of this document may be illegible in electronic image products. Images are produced from the best available original document.

CATABOLIC PATHWAY DIFFERENCES BETWEEN I-131 AND TC-99M

LABELED ALBUMIN COLLOIDS AND MICROAGGREGATES*

KENICHI KITANI, M.D., AND GEORGE V. TAPLIN, M.D.

THE DIVISION OF NUCLEAR MEDICINE

LOS ANGELES COUNTY HARBOR GENERAL HOSPITAL

TORRANCE, CALIFORNIA

AND

THE LABORATORY OF NUCLEAR MEDICINE AND RADIATION BIOLOGY

UNIVERSITY OF CALIFORNIA, LOS ANGELES, CALIFORNIA 90024

NOTICE

This report was prepared as an account of work sponsored by the United States Government. Neither the United States nor the United States Atomic Energy Commission, nor any of their employees, nor any of their contractors, subcontractors, or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness or usefulness of any information, apparatus, product or process disclosed, or represents that its use would not infringe privately owned rights.

* These studies were supported by Contract AT(04-1)GEN-12 between the Atomic Energy Commission and the University of California.

Radioiodinated albumin suspensions have been used for 10 years for liver-spleen-bone marrow scanning and longer for studying reticuloendothelial system (RES) functions. The colloidal size (10-20 nm) preparation has been most extensively studied, regarding its catabolism (1-5). The release rate of radioactivity from the liver following intravenous administration of ^{131}I (or ^{125}I) albumin colloids has been used as an index of Kupffer cell digestive function (1-5). Little is known about the catabolic pathways of $^{99\text{m}}\text{Tc}$ albumin suspensions. This paper describes several differences in the catabolism of ^{131}I vs $^{99\text{m}}\text{Tc}$ labeled albumin suspensions as determined in anesthetized dogs.

MATERIALS

Four types of radioalbumin suspensions were used. ^{131}I albumin suspensions were made from commercial ^{131}I human serum albumin. $^{99\text{m}}\text{Tc}$ albumin was prepared in our laboratory by a method described previously (3). Colloidal albumin suspensions were prepared by the following procedure. After adjusting the pH of the 0.1 percent radioalbumin to 9.0-10.0, the solution was heated in a boiling water bath for 10 minutes with gentle shaking. After cooling to room temperature, the pH was adjusted to 7.0. The material is slightly opalescent. Colloidal suspensions made by this method have an aggregate size of 10-20 nm. Microaggregate suspensions were prepared by the method of Yamada et al (6). Briefly, 0.1 percent radioalbumin at pH 5.2 is heated in a boiling water bath for 3.5 minutes with shaking which produces aggregates in the 10-20 μm size range. After cooling to room temperature, the suspension is ultrasonicated for 5 minutes, to reduce aggregate size to the 1-5 μm range. More than 90% of the radioactivity can be removed from the suspension by centrifugation at 3000 rpm for 10 minutes.

METHODS

Fourteen mongrel dogs of both sexes were studied following an overnight fast. After intravenous injection of each one of the radioalbumin preparations (< 1.0 mg albumin per dose), the following procedures were performed.

1. Blood radioactivity determinations: Heparinized blood samples were obtained at 2 minute intervals for the first 10 minutes, then at 15, 20, 30, 45, 60 minutes, and thereafter each 60 minutes for 4 hours. Two 1.0 ml plasma samples were prepared from each blood sample by centrifugation. The protein fraction of plasma samples was separated by repeated (3 times) precipitation with tannic acid (5%) and centrifugation. Plasma activity in the microaggregate study was determined from whole blood samples, and corrected for the hematocrit value of each sample. Samples were assayed in a well type scintillation counter.

2. Liver monitoring: Continuous recording of radioactivity over the liver area was performed with a collimated scintillation detector or a scintillation camera. Care was taken to position the collimated detector in a manner to avoid the registration of activity in the stomach for the ^{131}I preparations and for gallbladder activity with the $^{99\text{m}}\text{Tc}$ preparations.

3. Sequential abdominal imaging: Imaging was performed intermittently for 5 hours after injection, using a Dynacamera II.

These three procedures were performed separately on different occasions. Some studies were done simultaneously, when technically possible, for example, blood sampling and continuous external monitoring.

4. Separate sequential imaging studies were performed during the first 5 hours using $^{99\text{m}}\text{Tc}$ pertechnetate, $^{99\text{m}}\text{Tc}$ albumin, and Tc albumin macroaggregates for comparative purposes.

All dogs were pretreated with perchlorate for the Tc studies and with sodium iodide for those with ^{131}I . In three dogs, bile was collected via a common bile duct catheter between 3 and 4 hours following the injection of $^{99\text{m}}\text{Tc}$ albumin colloid. The bile samples were examined by paper chromatography using an 85% methyl alcohol-15% water solvent. Radioactivities in the chromatograms were recorded by a chromatoscanner. $^{99\text{m}}\text{Tc}$ pertechnetate was mixed with dog bile samples obtained before radioactive material injection, and similar chromatographic studies were performed.

RESULTS

Blood Disappearance Rate Differences

The half-time values ($t_{1/2}$) of the initial plasma radioactivity disappearance curves are summarized in Table 1. Both albumin microaggregate preparations had shorter $t_{1/2}$ values than those of colloidal size. The differences in half-time values for albumin suspensions of the same size were insignificant regardless of the label.

TABLE 1

Figure 1 shows the sequential changes in the plasma activity. In case of the ^{131}I colloid, nonprotein bound or "free" iodide activity appeared in the blood 15 to 20 minutes after injection and was the main cause of the secondary rise of total plasma activity, which remains elevated for several hours. ^{131}I albumin microaggregate preparations showed a similar increase of free ^{131}I in plasma but at much slower rates. With both $^{99\text{m}}\text{Tc}$ suspensions, a secondary rise of plasma activity was not observed, and both the total and protein bound activity levels continued to fall.

FIG. 1

Liver Release Rate Differences

Figure 2 shows the liver release rates of radioactivity for the four different albumin preparations. Counting rates for $^{99\text{m}}\text{Tc}$ preparations were

FIG. 2

corrected for physical decay. The ^{131}I albumin colloid curve shows a rapid decline, beginning 15-20 minutes after injection and by 3 hours, it decreased to 40% of the peak level. The ^{131}I microaggregate curve, on the other hand, shows a much slower decrease. By three hours, only 15% of the maximum amount had disappeared from the liver. The $^{99\text{m}}\text{Tc}$ albumin colloid curve shows a surprisingly slow liver rate, which is nearly the same as those of the two microaggregate preparations. The $^{99\text{m}}\text{Tc}$ microaggregate preparation has the slowest liver release rate.

Sequential Abdominal Imaging

Figures 3 and 4 shows the abdominal images obtained with four different preparations. With the ^{131}I colloid, the liver image becomes indistinct within 1 hour and by 2 to 3 hours activity in the stomach region becomes well visualized. Images following ^{131}I microaggregate injection show similar patterns but radioactivity in the stomach area is visualized much later (4-5 hours) and in smaller amounts (Fig. 3). The $^{99\text{m}}\text{Tc}$ suspensions show identical liver patterns. However, instead of revealing activity in the stomach in 2-3 hours the gallbladder becomes visible (Fig. 4). The amount of activity in the gallbladder is somewhat greater with the colloidal size preparations than with $^{99\text{m}}\text{Tc}$ microaggregates. In some cases, the small intestine is visualized by 3 to 4 hours with colloidal Tc preparations and neither the stomach nor the large intestine is seen during the first five hours. Figure 5 shows delayed abdominal images with other $^{99\text{m}}\text{Tc}$ compounds. The gallbladder was not visualized with any of these.

FIG. 3
FIG. 4

FIG. 5

Radiochromatography

Radiochromatograms of bile obtained from dogs given $^{99\text{m}}\text{Tc}$ albumin colloids intravenously, show a single peak of activity far from the origin. The R_f value is almost identical to that of $^{99\text{m}}\text{Tc}$ pertechnetate. The activity

in the bile could not be separated by centrifugation, nor could it be precipitated by tannic acid.

DISCUSSION

The observation of ^{131}I liver release, following albumin colloid and/or microaggregate injection and the re-entry of nonprotein iodide, or "free iodide" into the plasma plus its subsequent concentration in the stomach confirm previous findings with these materials (1-5,7). The disparity in liver release rates between the radioiodinated colloids and microaggregate suspensions has been explained by gross differences in size and surface area of the aggregates in the two preparations (6). The small colloidal ^{131}I albumin in trace doses is metabolized rapidly by the liver, whereas, the 100 times larger microaggregates in the same trace doses are handled much more slowly as if a loading dose had been given. Therefore, microaggregate preparations may be suitable in trace doses for the assessment of blood flow and proteolytic digestive function of the RES. Simultaneous blood flow and digestive function assessments are not valid with conventional small colloidal preparations given in trace doses; only blood flow estimation is possible with trace doses of this agent.

The slow liver release rates observed with the $^{99\text{m}}\text{Tc}$ albumin suspensions cannot be explained by a gross surface area difference. If the first degradation process of albumin aggregates in the Kupffer cells is hydrolysis of the albumin molecule, as Mego (8) and others (9) have indicated, the hydrolysis rates of ^{131}I and $^{99\text{m}}\text{Tc}$ albumin colloids of the same size should be similar regardless of the radioactive label. The relatively slow liver release rates of $^{99\text{m}}\text{Tc}$ vs ^{131}I albumin preparations may be due to differences in labeling sites on the albumin molecule and in catabolic processes.

With ^{131}I albumin colloids, deiodination occurs quickly with rapid release of free-iodide into the circulation (1,5-10). The longer retention of liver activity with Tc albumin preparations may indicate that their degradation products are retained in the liver longer than those of radioiodinated albumin preparations.

Gallbladder visualization with $^{99\text{m}}\text{Tc}$ albumin preparations supports a hepatobiliary pathway for $^{99\text{m}}\text{Tc}$ metabolite following the digestion in the Kupffer cells. Biliary excretion could explain the absence of a secondary rise in plasma nonprotein activity with both types of Tc preparations. The biliary excretion of $^{99\text{m}}\text{Tc}$ has not been described in previous animal studies. However, the authors have reported its biliary excretion in man via abdominal imaging, after the administration of $^{99\text{m}}\text{Tc}$ albumin microaggregate suspensions (11).

The similarity of the R_f value observed in radiochromatography between a possible Tc albumin metabolic excreted in dog bile, and Tc pertechnetate, does not necessarily mean that the Tc in the bile is pertechnetate ion. As shown in sequential abdominal images, following $^{99\text{m}}\text{Tc}$ pertechnetate injection, this ion does not have a significant biliary excretion pathway. Our current explanation is that the albumin aggregates are degraded in the Kupffer cells by proteolytic enzymes to smaller molecular entities in which they are released into the sinusoids and enter the hepatic cells for possible further catabolism and subsequent excretion in the bile. The chemical identity of the Tc compound(s) is unknown but most probably it is a human serum albumin degradation product.

ACKNOWLEDGEMENTS

The authors wish to express their gratitude to Drs. Gordon Lindenblad of Mallinkrodt Pharmaceuticals, St. Louis, Mo., and Paul Numerof of E.R. Squibb and Sons, N.Y.C. for donating supplies of radionuclides used in these studies; to Mary Lee Griswold for preparing the illustrations and the GEN-12 Contract between the USAEC and the University of California for support of this project.

REFERENCES

1. Biozzi G, Halpern BN, Stiffel C, et al: Quantitative study of the metabolic activity of the Kupffer cells on a heat denatured serum albumin labeled with ^{131}I . Brit J Exp Path 39: 510-518, 1958.
2. Taplin GV, Dore EK, Johnson DE: Clinical studies of reticuloendothelial functions with colloidal suspensions of human serum albumin ^{131}I . AEC report, Biology and Medicine UCLA 489, Sept. 20, 1961.
3. Taplin GV, Dore EK, Johnson DE: Reticuloendothelial functions in man. Tracer studies with colloidal suspensions of human albumin ^{131}I . Radioaktive Isotope in Klinik und Forschung, Urban and Schwarzenberg, Munich, Germany, 5, 346-361, 1963.
4. Taplin GV, Dore EK, Johnson DE: Hepatic blood flow and reticuloendothelial system studies with radiocolloids. Dynamic Clinical Studies with Radioisotopes, TID 7678, Proc. ORINS Symp. in Med. #8, 285-317, 1964.
5. Palmer DL, Rifkind D, Brown DW: ^{131}I labeled colloidal serum albumin in the study of reticuloendothelial function; the distribution of free and colloid-bound radioiodide. J Lab Clin Med 68: 972-980, 1967.
6. Yamada H, Johnson DE, Griswold ML, et al: Radioalbumin microaggregates for reticuloendothelial organ scanning and function assessment. J Nucl Med 10: 453-454, 1969.
7. Palmer DL, Rifkind D, Brown DW: ^{131}I -labeled colloidal human serum albumin in the study of reticuloendothelial system function. III. Phagocytosis and catabolism compared in normal, leukemic, and immunosuppressed human subjects. J Infect Dis 123: 465-469, 1971.
8. Mego JL, Bertini F, McQueen D: The use of formaldehyde-treated ^{131}I -albumin in the study of digestive vacuoles and some properties of these particles from mouse liver. J Cell Biol 32: 699-706, 1967.

9. Davies M, Lloyd JB, Beck F: The effect of Trypan blue, suramin and aurothiomalate on the breakdown of ¹²⁵I-labeled albumin within rat liver lysosomes. Biochem J 121: 21-26, 1971.

10. Taplin GV, Johnson DE, Dore EK, et al: Suspensions of radioalbumin aggregates for photoscanning of the liver, spleen, lung and other organs. J Nucl Med 5: 259-275, 1964.

11. Kitani K, Taplin GV, Hayes M, et al: Visualizing biliary excretion of ^{99m}Tc-albumin degradation products (A test for Kupffer cell digestive function?). J Nucl Med 12: 373, 1971.

TABLE 1. DISAPPEARANCE RATES FOR THE FOUR RADIOALBUMIN
PARTICLE SUSPENSIONS

	<u>T 1/2 IN MIN $\pm$ SD</u>	<u>NO OF ANIMALS</u>
^{131}I ALBUMIN COLLOIDS	4.3 $\pm$ 0.5	6
^{131}I ALBUMIN MICROAGGREGATES	2.3 $\pm$ 0.4	5
$^{99\text{m}}\text{Tc}$ ALBUMIN COLLOIDS	4.5 $\pm$ 0.3	7
$^{99\text{m}}\text{Tc}$ ALBUMIN MICROAGGREGATES	2.5 $\pm$ 0.3	8

LEGENDS TO FIGURES

- Figure 1 Total and protein bound plasma activity levels after i.v. injection of four different radioalbumin preparations.
- Figure 2 Liver activity release rates of four different radioalbumin preparations.
- Figure 3 Sequential abdominal images with ^{131}I albumin colloids and microaggregates.
- Figure 4 Sequential abdominal images with $^{99\text{m}}\text{Tc}$ albumin colloids and microaggregates.
- Figure 5 Delayed images (4 hrs) with $^{99\text{m}}\text{Tc}$ pertechnetate, iron-ascorbic-acid complex, albumin solution and albumin macroaggregates. None of these preparations showed scan evidence of biliary excretion at 4 hours.

—○— TOTAL PLASMA ACTIVITY

-x-x- PROTEIN BOUND PLASMA ACTIVITY

^{131}I ALBUMIN COLLOIDS

15 MIN.

1 Hr.

2 Hrs.

3 Hrs.

5 Hrs.

^{131}I ALBUMIN MICROAGGREGATES

15 MIN.

1 Hr.

2 Hrs.

3 Hrs.

5 Hrs.

^{99m}Tc ALBUMIN COLLOIDS

15 MIN.

1.5 Hrs.

3 Hrs.

4 Hrs.

5 Hrs.

^{99m}Tc ALBUMIN MICROAGGREGATES

15 MIN.

1.5 Hrs.

3 Hrs.

4 Hrs.

5 Hrs.

Tc Iron Ascorbate

4 Hours

Tc Pertechnetate

WITH

Perchlorate

4 Hours

WITHOUT

Tc Albumin

4 Hours

Tc Albumin Macroaggregates

30 Min.

4 Hours